Relay Therapeutics (RLAY) to Release Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) is set to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative return on equity of 42.43% and a negative net margin of 1,263.49%. During the same quarter last year, the firm posted ($0.56) earnings per share. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Trading Up 3.9 %

Shares of Relay Therapeutics stock traded up $0.24 on Friday, reaching $6.40. 77,366 shares of the company were exchanged, compared to its average volume of 1,139,714. The stock has a fifty day moving average price of $8.33 and a 200-day moving average price of $8.84. Relay Therapeutics has a fifty-two week low of $5.70 and a fifty-two week high of $13.32. The firm has a market capitalization of $846.98 million, a price-to-earnings ratio of -2.29 and a beta of 1.63.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on RLAY. Stifel Nicolaus raised their price objective on Relay Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of Relay Therapeutics in a report on Thursday, February 22nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Relay Therapeutics presently has an average rating of “Buy” and a consensus target price of $26.00.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.